Immunotherapy company Stellar Biotechnologies Inc (Nasdaq:SBOT) stated on Tuesday that it recorded a net loss of USD1.41m (USD0.26 per basic share) for the three months ended 31 December 2018.
This is compared with a net loss of USD1.40m (USD0.93 per basic share) for the first quarter of the prior fiscal year.
Total revenues of USD0.05m were generated for the three months ended 31 December 2018, up by USD0.03m over the revenues USD0.02m for the same period last year primarily due to increased sales of higher value, clinical-grade KLH products.
Research and development expenses of USD0.47m were recorded for the three months ended 31 December 2018, a decline by USD0.16m from the R&D of USD0.63m for the same period last year, which was primarily due to a decrease in contracted research services and materials.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government